These observations are in line with the reported loss of PTEN immunolabeling in a variable percentage (30%−80%) of human gliomas depending on the type and grade of tumors included in the study [35,36,37,38,39,40,41,44,45,46,47,48]. The gene discussed is PTEN; the disease is central nervous system cancer.